FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Floris de Jong

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Physiology

Co-author Network

Publications

TOP 3
Karel Eechoute; Martin N Fransson; Lena E Friberg; Walter J Loos; Ron H J Mathijssen; A K L Reyners; Gaia Schiavon; Alex Sparreboom; Winette T A van der Graaf; Jaap Verweij; Erik A C Wiemer; Floris A de Jong; Ugo De Giorgi
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.
Jessica van der Bol; Walter J Loos; Floris A de Jong; Esther van Meerten; Inge R H M Konings; Mei H Lam; Peter de Bruijn; Erik A C Wiemer; Jaap Verweij; Ron H J Mathijssen
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
Jessica M van der Bol; Theo J Visser; Walter J Loos; Floris A de Jong; Erik A C Wiemer; Maarten O van Aken; A S T Planting; Jan H Schellens; Jaap Verweij; Ron H J Mathijssen
Effects of methimazole on the elimination of irinotecan.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Floris de Jong (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Karel Eechoute; Martin N Fransson; Lena E Friberg; Walter J Loos; Ron H J Mathijssen; A K L Reyners; Gaia Schiavon; Alex Sparreboom; Winette T A van der Graaf; Jaap Verweij; Erik A C Wiemer; Floris A de Jong; Ugo De Giorgi
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(20):5780-7.
2011: Jessica van der Bol; Walter J Loos; Floris A de Jong; Esther van Meerten; Inge R H M Konings; Mei H Lam; Peter de Bruijn; Erik A C Wiemer; Jaap Verweij; Ron H J Mathijssen
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
European journal of cancer (Oxford, England : 1990) 2011;47(6):831-8.
2011: Jessica M van der Bol; Theo J Visser; Walter J Loos; Floris A de Jong; Erik A C Wiemer; Maarten O van Aken; A S T Planting; Jan H Schellens; Jaap Verweij; Ron H J Mathijssen
Effects of methimazole on the elimination of irinotecan.
Cancer chemotherapy and pharmacology 2011;67(1):231-6.
2010: Jessica M van der Bol; Ron H J Mathijssen; Geert-Jan M Creemers; A S T Planting; Walter J Loos; Erik A C Wiemer; Lena E Friberg; Jaap Verweij; Alex Sparreboom; Floris A de Jong
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(2):736-42.
2010: Jessica van der Bol; Floris A de Jong; Ron van Schaik; Alex Sparreboom; Marianne A van Fessem; Fleur E van de Geijn; P L A van Daele; Jaap Verweij; Stefan Sleijfer; Ron H J Mathijssen
Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.
The oncologist 2010;15(10):1063-72.
2008: Floris A de Jong; Jessica van der Bol; Ron H J Mathijssen; Teun van Gelder; Erik A C Wiemer; Alex Sparreboom; Jaap Verweij
Renal function as a predictor of irinotecan-induced neutropenia.
Clinical pharmacology and therapeutics 2008;84(2):254-62.
2008: Floris A de Jong; Alex Sparreboom; Jaap Verweij; Ron H J Mathijssen
Lifestyle habits as a contributor to anti-cancer treatment failure.
European journal of cancer (Oxford, England : 1990) 2008;44(3):374-82.
2008: Paul Hamberg; Floris A de Jong; Dieta Brandsma; Jaap Verweij; Stefan Sleijfer
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
Acta oncologica (Stockholm, Sweden) 2008;47(5):974-8.
2007: Frederike K Engels; Floris A de Jong; Ron H J Mathijssen; Joëlle A Erkens; Ron Herings; Jaap Verweij
Medicinal cannabis in oncology.
European journal of cancer (Oxford, England : 1990) 2007;43(18):2638-44.
2007: Floris A de Jong; Jessica van der Bol; Ron H J Mathijssen; Walter J Loos; Ron A A Mathôt; Jos J E M Kitzen; Martin J van den Bent; Jaap Verweij
Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity.
Cancer biology & therapy 2007;6(9):1368-74.
2007: Ron H J Mathijssen; Floris A de Jong; Walter J Loos; Jessica van der Bol; Jaap Verweij; Alex Sparreboom
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
The oncologist 2007;12(8):913-23.
2007: Jessica van der Bol; Ron H J Mathijssen; Walter J Loos; Lena E Friberg; Ron van Schaik; M J A de Jonge; A S T Planting; Jaap Verweij; Alex Sparreboom; Floris A de Jong
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2719-26.
2007: Frederike K Engels; Floris A de Jong; Alex Sparreboom; Ron A A Mathot; Walter J Loos; Jos J E M Kitzen; Peter de Bruijn; Jaap Verweij; Ron H J Mathijssen
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
The oncologist 2007;12(3):291-300.
2007: Floris A de Jong; Tiffany J Scott-Horton; D L Kroetz; howard mcleod; Lena E Friberg; Ron H J Mathijssen; Jaap Verweij; Sharon Marsh; Alex Sparreboom
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
Clinical pharmacology and therapeutics 2007;81(1):42-9.
2006: Floris A de Jong; Jos J E M Kitzen; Peter de Bruijn; Jaap Verweij; Walter J Loos
Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.
Cancer biology & therapy 2006;5(9):1105-10.
2006: Floris A de Jong; Diederik F S Kehrer; Ron H J Mathijssen; Geert-Jan Creemers; Peter de Bruijn; Ron van Schaik; A S T Planting; Ate van der Gaast; Ferry A L M Eskens; Jos Th P Janssen; Jan B Ruit; Jaap Verweij; Alex Sparreboom; M J A de Jonge
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
The oncologist 2006;11(8):944-54.
2006: Erin R Gardner; Herman Burger; Ron van Schaik; Allan T van Oosterom; Ernst A de Bruijn; Gunther Guetens; Hans Prenen; Floris A de Jong; Sharyn D Baker; Susan E Bates; William D Figg; Jaap Verweij; Alex Sparreboom; Kees Nooter
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
Clinical pharmacology and therapeutics 2006;80(2):192-201.
2006: Metin Tascilar; Floris A de Jong; Jaap Verweij; Ron H J Mathijssen
Complementary and alternative medicine during cancer treatment: beyond innocence.
The oncologist 2006;11(7):732-41.
2006: Paul Hamberg; Floris A de Jong; Joke G Boonstra; Jaap van Doorn; Jaap Verweij; Stefan Sleijfer
Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(18):e30-1.
2006: Floris A de Jong; M J A de Jonge; Jaap Verweij; Ron H J Mathijssen
Role of pharmacogenetics in irinotecan therapy.
Cancer letters 2006;234(1):90-106.
2005: Floris A de Jong; Frederike K Engels; Ron H J Mathijssen; Lia van Zuylen; Jaap Verweij; Remco P H Peters; Alex Sparreboom
Medicinal cannabis in oncology practice: still a bridge too far?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2886-91.
2005: Otto Soepenberg; Herlinde Dumez; Jaap Verweij; Floris A de Jong; M J A de Jonge; José Thomas; Ferry A L M Eskens; Ron van Schaik; Johan Selleslach; Judith ter Steeg; Patricia Lefebvre; Sylvie Assadourian; Ger-Jan Sanderink; Alex Sparreboom; Allan T van Oosterom
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1504-11.
2004: Ron H J Mathijssen; Floris A de Jong; Ron van Schaik; Erin R Lepper; Lena E Friberg; Trinet Rietveld; Peter de Bruijn; Wilfried J Graveland; William D Figg; Jaap Verweij; Alex Sparreboom
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Journal of the National Cancer Institute 2004;96(21):1585-92.
2004: Floris A de Jong; Ron H J Mathijssen; J Verweij
Limited potential of hepatic arterial infusion of irinotecan.
Journal of chemotherapy (Florence, Italy) 2004;16 Suppl 5():48-50.
2004: Floris A de Jong; Sharon Marsh; Ron H J Mathijssen; Cristi King; Jaap Verweij; Alex Sparreboom; howard mcleod
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5889-94.
2004: Floris A de Jong; Ron H J Mathijssen; Rujia Xie; Jaap Verweij; Alex Sparreboom
Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4068-71.
2003: Floris A de Jong; Jaap Verweij
Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
Expert review of anticancer therapy 2003;3(6):757-66.
2003: Floris A de Jong; Ron H J Mathijssen; Peter de Bruijn; Walter J Loos; Jaap Verweij; Alex Sparreboom
Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;795(2):383-8.